2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk

Autor: Mach, François, Baigent, Colin, Catapano, Alberico L, Koskinas, Konstantinos C, Casula, Manuela, Badimon, Lina, Chapman, M John, De Backer, Guy G, Delgado, Victoria, Ference, Brian A, Graham, Ian M, Halliday, Alison, Landmesser, Ulf, Mihaylova, Borislava, Pedersen, Terje R, Riccardi, Gabriele, Richter, Dimitrios J, Sabatine, Marc S, Taskinen, Marja-Riitta, Tokgozoglu, Lale, Wiklund, Olov, Mueller, Christian, Drexel, Heinz, Aboyans, Victor, Corsini, Alberto, Doehner, Wolfram, Farnier, Michel, Gigante, Bruna, Kayikcioglu, Meral, Krstacic, Goran, Lambrinou, Ekaterini, Lewis, Basil S, Masip, Josep, Moulin, Philippe, Petersen, Steffen, Petronio, Anna Sonia, Piepoli, Massimo Francesco, Pintó, Xavier, Räber, Lorenz, Ray, Kausik K, Reiner, Željko, Riesen, Walter F, Roffi, Marco, Schmid, Jean- Paul, Shlyakhto, Evgeny, Simpson, Iain A, Stroes, Erik, Sudano, Isabella, Tselepis, Alexandros D, Viigimaa, Margus, Vindis, Cecile, Vonbank, Alexander, Vrablik, Michal, Vrsalovic, Mislav, Zamorano, José Luis, Collet, Jean- Philippe, John Chapman, M, Windecker, Stephan, Collet, Jean-Philippe, Dean, Veronica, Fitzsimons, Donna, Gale, Chris P, Grobbee, Diederick, Halvorsen, Sigrun, Hindricks, Gerhard, Iung, Bernard, Jüni, Peter, Katus, Hugo A, Leclercq, Christophe, Lettino, Maddalena, Merkely, Bela, Sousa-Uva, Miguel, Touyz, Rhian M, Nibouche, Djamaleddine, Zelveian, Parounak H, Siostrzonek, Peter, Najafov, Ruslan, van de Borne, Philippe, Pojskic, Belma, Postadzhiyan, Arman, Kypris, Lambros, Špinar, Jindřich, Larsen, Mogens Lytken, Eldin, Hesham Salah, Strandberg, Timo E, Ferrières, Jean, Agladze, Rusudan, Laufs, Ulrich, Rallidis, Loukianos, Bajnok, László, Gudjónsson, Thorbjörn, Maher, Vincent, Henkin, Yaakov, Gulizia, Michele Massimo, Mussagaliyeva, Aisulu, Bajraktari, Gani, Kerimkulova, Alina, Latkovskis, Gustavs, Hamoui, Omar, Slapikas, Rimvydas, Visser, Laurent, Dingli, Philip, Ivanov, Victoria, Boskovic, Aneta, Nazzi, Mbarek, Visseren, Frank, Mitevska, Irena, Retterstøl, Kjetil, Jankowski, Piotr, Fontes-Carvalho, Ricardo, Gaita, Dan, Ezhov, Marat, Foscoli, Marina, Giga, Vojislav, Pella, Daniel, Fras, Zlatko, de Isla, Leopoldo Perez, Hagström, Emil, Lehmann, Roger, Abid, Leila, Ozdogan, Oner, Mitchenko, Olena, Patel, Riyaz S, ESC Scientific Document Group
Přispěvatelé: Service d’Endocrinologie, Métabolisme et Prévention des Risques Cardio-Vasculaires [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Sorbonne Université - Faculté de Médecine (SU FM), Sorbonne Université (SU), University of Zurich, Mach, François
Jazyk: angličtina
Rok vydání: 2020
Předmět:
medicine.medical_specialty
Treatment adherence
Evinacumab
[SDV]Life Sciences [q-bio]
Very low-density lipoproteins
610 Medicine & health
Lipoprotein remnants
030204 cardiovascular system & hematology
Guidelines
Total cardiovascular risk
2705 Cardiology and Cardiovascular Medicine
Treatment (lifestyle)
03 medical and health sciences
0302 clinical medicine
Risk Factors
medicine
Humans
030212 general & internal medicine
High-density lipoproteins
Intensive care medicine
ComputingMilieux_MISCELLANEOUS
Dyslipidaemias
Triglycerides
Dyslipidemias
Task force
business.industry
Treatment (drugs)
Lipids
Coronary heart disease
3. Good health
Treatment (adherence)
Cholesterol
Cardiovascular Diseases
Heart Disease Risk Factors
10209 Clinic for Cardiology
European atherosclerosis society
LDL Cholesterol Lipoproteins
Low-density lipoproteins
Lipid modification
Cardiology and Cardiovascular Medicine
business
Familial hypercholesterolaemia
Apolipoprotein B
All cause mortality
Guidelines • dyslipidaemias • cholesterol • triglycerides • low-density lipoproteins • high-density lipoproteins • apolipoprotein B • lipoprotein(a) • lipoprotein remnants • total cardiovascular risk • treatment (lifestyle) • treatment (drugs) • treatment (adherence) • very low-density lipoproteins • familial hypercholesterolaemia
Lipoprotein(a)
Zdroj: European Heart Journal
European Heart Journal, Oxford University Press (OUP): Policy B, 2020, 41 (1), pp.111-188. ⟨10.1093/eurheartj/ehz455⟩
Mach, François; Baigent, Colin; Catapano, Alberico L; Koskinas, Konstantinos C.; Casula, Manuela; Badimon, Lina; Chapman, M John; De Backer, Guy G; Delgado, Victoria; Ference, Brian A; Graham, Ian M; Halliday, Alison; Landmesser, Ulf; Mihaylova, Borislava; Pedersen, Terje R; Riccardi, Gabriele; Richter, Dimitrios J; Sabatine, Marc S; Taskinen, Marja-Riitta; Tokgozoglu, Lale; ... (2020). 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European heart journal, 41(1), pp. 111-188. Oxford University Press 10.1093/eurheartj/ehz455
ISSN: 0195-668X
1522-9645
DOI: 10.7892/boris.147206
Popis: The previous ESC/EAS lipid Guidelines were published in August 2016. The emergence of a substantial body of evidence over the last few years has required new, up-to-date Guidelines. New evidence has confirmed that the key initiating event in atherogenesis is the retention of low- density lipoprotein (LDL) cholesterol (LDL-C) and other cholesterol-rich apolipoprotein (Apo) B containing lipoproteins within the arterial wall. Several recent placebo-controlled clinical studies have shown that the addition of either ezetimibe or anti-proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAbs) to statin therapy provides a further reduction in atherosclerotic cardiovascular disease (ASCVD) risk, which is directly and positively correlated with the incrementally achieved absolute LDL-C reduction. Furthermore, these clinical trials have clearly indicated that the lower the achieved LDL-C values, the lower the risk of future cardiovascular (CV) events, with no lower limit for LDL-C values, or ‘J’-curve effect.
Databáze: OpenAIRE
Externí odkaz: